Whitehawk Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
About Whitehawk Therapeutics
Pharmaceutical Preparations, SIC 2834
This clinical-stage biopharmaceutical company develops antibody-drug conjugates to treat cancer. Its pipeline features three investigational therapies: HWK-007 for solid tumors such as non-small cell lung and ovarian cancers; HWK-016 for gynecological cancers including ovarian and endometrial; and HWK-206 for small cell lung cancer and neuroendocrine tumors. After divesting its FYARRO business in 2025, the company maintains no active commercial segments. Its pipeline targets adult patients suffering from advanced or metastatic solid tumors refractory to standard therapies.
The organization operates via a virtual model, outsourcing research, development, and manufacturing to partner organizations. It maintains worldwide development and commercialization rights for its therapeutic candidates. Clinical activities focus on the United States, where multicenter Phase 1 trials evaluate its leading programs under Food and Drug Administration clearance. The provided text does not state the location of the company's headquarters.
Summary of the business section of Whitehawk Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Whitehawk Therapeutics, Inc.
- Headquarters
- Morristown, NJ
- Address
- 2 Headquarters Plaza, East Building, 11th Floor 07960
- Phone
- (551) 321-2234
- Employees
- 23, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- WHWK
- Exchange
- Nasdaq
- IPO date
- Feb 16, 2018
- Shares outstanding
- 57M, Aug 3, 2026
- Public float
- $64.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16.67 reverse, Nov 10, 2021; 1-for-15 reverse, Aug 27, 2021; 1-for-6.75 reverse, May 15, 2017
- SEC CIK
- 1422142
- CUSIP
- 00032Q104
- ISIN
- US00032Q1040
- LEI
- 549300G3U7TKW1M58L09
- EIN
- 61-1547850
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David James Lennon | CHIEF EXECUTIVE OFFICER, Director | 569,643 |
| David Dornan | Chief Scientific Officer | – |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | 333,489 |
| Margaret Dugan | Chief Medical Officer | 19,132 |
| Bryan Ball | See remarks | 448,126 |
| Vijay K. Iyengar | Director | – |
| Anupam Dalal | Director | 4,687,042 |
| Behzad Aghazadeh | Director | 2,211,752 |
| Capital Advisors LLC Avoro | Director | – |
| Ventures LLC Avoro | Director | 3,471,752 |
| Richard E. Maroun | Director | – |
| Caley Castelein | Director | 2,440,794 |
| Emma Reeve | Director | – |
| Neil Desai | Director | 1,171,543 |
| Mohammad Hirmand | Director | – |
| Baiteng Zhao | Director | 1,250,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Lennon | $3.40M | $4.49M | $1.96M | $19 | – |
| FY2024 David Lennon | $1.01M | $1.61M | $1.19M | $25 | – |
| FY2024 Lennon | $1.01M | $1.61M | $1.19M | $25 | – |
| FY2023 Brendan Delaney | $1.65M | -$1.29M | $1.82M | $16 | – |
| FY2023 David Lennon | $2.14M | $1.09M | $1.82M | $16 | – |
| FY2023 Delaney | $1.65M | $1.29M | $1.82M | $16 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 23 full-time or part-time employees.”
Corporate history
Events identified from SEC filings